Construction of a new patient-derived xenograft model of human liver cancer in mice with normal immunity

Huixin TANG; Shanshan LI; Feng HONG; Yanzhen BI; Quanyi WANG; Xiaobei ZHANG; Shumin CHENG; Zhongping DUAN; Zhenfeng SHU; Yu CHEN

doi:10.3969/j.issn.1001-5256.2021.11.019

Volume 37 Issue 11

Nov. 2021

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2021 > 37(11): 2584-2588

PDF( 3030 KB)

Construction of a new patient-derived xenograft model of human liver cancer in mice with normal immunity

DOI: 10.3969/j.issn.1001-5256.2021.11.019

1.
The Fourth Liver Disease Center, Beijing YouAn Hospital, Capital Medical University, Beijing 100069, China
2.
Shanghai Meifeng Biotechnology Co., Ltd., Shanghai 201203, China
3.
Department of Infectious Diseases, Qingdao Municipal Hospital, Qingdao, Shandong 266011, China
4.
Institute of Liver Diseases, Affiliated Hospital of Jining Medical University, Jining, Shandong 272000, China
5.
Clinical College of Jining Medical University, Jining, Shandong 272000, China
6.
Beijing Municipal Key Laboratory of Liver Failure and Artificial Liver Treatment Research, Beijing 100069, China

Research funding:

National Natural Science Foundation of China (81170395);

National Natural Science Foundation of China (81570556);

Chinese foundation for hepatitis prevention and control—TianQing liver disease research fund subject (TQGB20210013);

National Key R&D Program of China (2017YFA0103000);

National Science and Technology Key Project on "Major Infectious Diseases such as HIV/AIDS, Viral Hepatitis Preventon and Treatment" (2017ZX10203201-005);

Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support (ZYLX201806)

Received Date: 2021-04-13
Accepted Date: 2021-05-24
Published Date: 2021-11-20

Abstract

Abstract

Objective To establish a new patient-derived xenograft (PDX) model of human liver cancer by inoculating the complex of human primary liver cancer cells and a novel microcarrier (microcarrier 6) into mice with normal immune function. Methods Primary liver cancer cells were isolated and extracted from the fresh human liver cancer tissue of five patients and were then co-cultured with microcarrier 6 to construct a three-dimensional tumor cell culture model in vitro. According to the type of graft, 75 male C57BL/6 mice were divided into cell control group, microcarrier control group, and experimental group (each sample corresponded to three groups, with 15 groups in total and 5 mice in each group). The liver cancer cell-microcarrier complex was implanted into the mice by subcutaneous inoculation, and tumor formation time, tumor formation rate, and histopathological manifestations were observed. The Fisher's exact test was used for comparison of categorical data between two groups. Results As for the liver cancer cells from the five patients, tumor formation was observed in the mice corresponding to three patients. In these three experiments, tumor formation was not observed in the control groups and was only observed in the experimental groups, and 12 of the 15 mice in the experimental groups had successful tumor formation, with a tumor formation rate as high as 80%, which was significantly different from that in the cell control groups and the microcarrier control groups (all P < 0.05). The tumor formation time was 5-7 days; the xenograft tumor grew rapidly, and HE staining showed nested or flaky cells with obvious heteromorphism, with the presence of pathological mitosis; immunohistochemical staining showed positive CK8/18, Hep, and Gpc-3, which was in accordance with the characteristics of human liver cancer cells. Conclusion This experiment successfully establishes a new PDX model of human liver cancer based on the complex of microcarrier 6 and human primary liver cancer cells in mice with normal immunity. This model can be used to better elucidate the mechanism of the development and progression of liver cancer in the body with normal immunity, and besides, it also provides a new animal model with higher value for the precise treatment of liver cancer.

FullText(HTML)

References(18)

References

[1]	BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. DOI: 10.3322/caac.21492.
[2]	LI L, CHEN J, CHEN X, et al. Serum miRNAs as predictive and preventive biomarker for pre-clinical hepatocellular carcinoma[J]. Cancer Lett, 2016, 373(2): 234-240. DOI: 10.1016/j.canlet.2016.01.028.
[3]	SIEGEL RL, MILLER KD, JEMAL A. Cancer Statistics, 2017[J]. CA Cancer J Clin, 2017, 67(1): 7-30. DOI: 10.3322/caac.21387.
[4]	IZUMCHENKO E, MEIR J, BEDI A, et al. Patient-derived xenografts as tools in pharmaceutical development[J]. Clin Pharmacol Ther, 2016, 99(6): 612-621. DOI: 10.1002/cpt.354.
[5]	POMPILI L, PORRU M, CARUSO C, et al. Patient-derived xenografts: A relevant preclinical model for drug development[J]. J Exp Clin Cancer Res, 2016, 35(1): 189. DOI: 10.1186/s13046-016-0462-4.
[6]	XU C, LI X, LIU P, et al. Patient-derived xenograft mouse models: A high fidelity tool for individualized medicine[J]. Oncol Lett, 2019, 17(1): 3-10. DOI: 10.3892/ol.2018.9583.
[7]	BI YZ, KONG LB, GAO PF, et al. Construction of a normal immune mouse human gastric cancer transplantation model based on microcarrier 6[J]. Chin J Clin Oncol, 2017, 44(5): 199-203. DOI: 10.3969/j.issn.1000-8179.2017.05.168. 毕研贞, 孔令斌, 高鹏飞, 等. 基于microcarrier 6构建正常免疫小鼠人胃癌移植模型[J]. 中国肿瘤临床, 2017, 44(5): 199-203. DOI: 10.3969/j.issn.1000-8179.2017.05.168.
[8]	WANG QY, SUN FQ, BI YZ, et al. Establishment of microcarrier human gastric cancer animal model and discussion of pathological characteristics[J]. Chin J Gen Surg, 2017, 32(10): 895-896. DOI: 10.3760/cma.j.issn.1007-631X.2017.10.031. 王全义, 孙富强, 毕研贞, 等. 微载体人胃癌动物模型的建立及其病理特征的探讨[J]. 中华普通外科杂志, 2017, 32(10): 895-896. DOI: 10.3760/cma.j.issn.1007-631X.2017.10.031.
[9]	HUANG R, HONG F, BI YZ, et al. Establishment of primary ovarian cancer model in mice with normal immunity[J]. Progr Obstetr Gynecol, 2018, 27(12): 901-904. DOI: 10.13283/j.cnki.xdfckjz.2018.12.004. 黄蓉, 洪丰, 毕研贞, 等. 正常免疫鼠人原代卵巢癌模型的建立[J]. 现代妇产科进展, 2018, 27(12): 901-904. DOI: 10.13283/j.cnki.xdfckjz.2018.12.004.
[10]	KUDO M. Systemic therapy for hepatocellular carcinoma: 2017 update[J]. Oncology, 2017, 93(Suppl 1): 135-146. DOI: 10.1159/000481244.
[11]	GRANDHI MS, KIM AK, RONNEKLEIV-KELLY SM, et al. Hepatocellular carcinoma: From diagnosis to treatment[J]. Surg Oncol, 2016, 25(2): 74-85. DOI: 10.1016/j.suronc.2016.03.002.
[12]	RICH NE, YOPP AC, SINGAL AG. Medical management of hepatocellular carcinoma[J]. J Oncol Pract, 2017, 13(6): 356-364. DOI: 10.1200/JOP.2017.022996.
[13]	ZHU J, YIN T, XU Y, et al. Therapeutics for advanced hepatocellular carcinoma: Recent advances, current dilemma, and future directions[J]. J Cell Physiol, 2019, 234(8): 12122-12132. DOI: 10.1002/jcp.28048.
[14]	YAN Y, CHEN N, WANG Y, et al. The application of antitumor drug-targeting models on liver cancer[J]. Drug Deliv, 2016, 23(5): 1667-1675. DOI: 10.3109/10717544.2015.1064188.
[15]	WEBER A, O'CONNOR T, HEIKENWALDER M. Next generation of preclinical liver cancer models[J]. Clin Cancer Res, 2015, 21(19): 4254-4256. DOI: 10.1158/1078-0432.CCR-15-1152.
[16]	OKADA S, VAETEEWOOTTACHARN K, KARIYA R. Establishment of a patient-derived tumor xenograft model and application for precision cancer medicine[J]. Chem Pharm Bull (Tokyo), 2018, 66(3): 225-230. DOI: 10.1248/cpb.c17-00789.
[17]	CHO SY, KANG W, HAN JY, et al. An integrative approach to precision cancer medicine using patient-derived xenografts[J]. Mol Cells, 2016, 39(2): 77-86. DOI: 10.14348/molcells.2016.2350.
[18]	ZHENG MJ, WANG J, CHEN YW, et al. A novel mouse model of gastric cancer with human gastric microenvironment[J]. Cancer Lett, 2012, 325(1): 108-115. DOI: 10.1016/j.canlet.2012.06.011.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(5) / Tables(2)

Get Citation

PDF

XML

Article Metrics

Article views (1330) PDF downloads(100)

Construction of a new patient-derived xenograft model of human liver cancer in mice with normal immunity

DOI: 10.3969/j.issn.1001-5256.2021.11.019

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Construction of a new patient-derived xenograft model of human liver cancer in mice with normal immunity

DOI: 10.3969/j.issn.1001-5256.2021.11.019

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content